GlassScriptPhysician profile
Michael Steven Davis
NPI 1124064225
$10,881.46
in general payments reported to CMS, 2019-2025
54 companies · $2,220 in 2025
The $2,220 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $456 · 2021: $616 · 2022: $1,931 · 2023: $1,575 · 2024: $2,549 · 2025: $2,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,344.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,700.03 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $1,358.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $780.29 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $638.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $483.75 | 2019-2025 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $475.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $405.98 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $392.91 | 2022-2025 | |
| Pfizer INC. | $367.07 | 2019-2025 | |
| Glaxosmithkline, LLC. | $321.09 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $276.53 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.91 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $261.31 | 2019-2025 | Verquvo, Belsomra, Lagevrio |
| Takeda Pharmaceuticals U.S.A., INC. | $245.42 | 2019-2024 | Trintellix |
| Mylan Specialty L.P. | $229.24 | 2021-2024 | Yupelri |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.